Shionogi & Co., Ltd.

DB:SH0 Stock Report

Market Cap: €11.4b

Shionogi Past Earnings Performance

Past criteria checks 2/6

Shionogi has been growing earnings at an average annual rate of 9.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8.2% per year. Shionogi's return on equity is 11.7%, and it has net margins of 36.9%.

Key information

9.4%

Earnings growth rate

11.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate8.2%
Return on equity11.7%
Net Margin36.9%
Next Earnings Update31 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shionogi makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:SH0 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24418,510154,57095,203112,261
30 Jun 24423,356150,105100,502107,075
31 Mar 24435,081162,03094,986102,640
31 Dec 23425,157154,45894,611100,217
30 Sep 23506,446218,29494,637100,868
30 Jun 23464,156192,80594,381104,859
31 Mar 23426,684184,96593,637102,392
31 Dec 22453,859200,91492,02199,585
30 Sep 22340,832118,31890,14693,550
30 Jun 22338,012116,66988,57480,797
31 Mar 22335,138114,18587,87772,996
31 Dec 21292,38496,78588,69763,234
30 Sep 21293,810115,60889,47857,570
30 Jun 21294,740122,56089,27156,812
31 Mar 21297,177111,85888,38754,249
31 Dec 20304,276117,42244,76487,183
30 Sep 20320,946119,95860,14372,803
30 Jun 20325,548119,31175,13660,115
31 Mar 20333,371122,19391,80247,949
31 Dec 19351,993129,25987,81068,325
30 Sep 19356,395126,47990,62168,325
30 Jun 19354,422125,28590,54668,325
31 Mar 19363,721132,759101,97868,325
31 Dec 18346,547123,483106,51659,945
30 Sep 18340,698116,426105,02159,945
30 Jun 18358,168124,748105,44059,945
31 Mar 18344,667108,86695,59259,945
31 Dec 17345,71996,065100,38559,907
30 Sep 17355,961103,01797,66559,907
30 Jun 17340,75587,35396,83559,907
31 Mar 17338,89083,87993,02759,907
31 Dec 16340,58392,55997,88949,787
30 Sep 16326,79576,49998,23349,787
30 Jun 16319,26869,56696,04749,787
31 Mar 16309,97366,68794,02149,787
31 Dec 15299,64559,46892,42448,870
30 Sep 15282,42855,73691,48448,870
30 Jun 15275,11743,39590,99748,870
31 Mar 15273,99144,06092,56648,870
31 Dec 14271,88730,85791,52551,924
30 Sep 14280,84430,13692,21151,924
30 Jun 14285,18941,30794,34451,924
31 Mar 14289,71741,83196,24351,924
31 Dec 13289,55975,62294,19053,021

Quality Earnings: SH0 has high quality earnings.

Growing Profit Margin: SH0's current net profit margins (36.9%) are lower than last year (43.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SH0's earnings have grown by 9.4% per year over the past 5 years.

Accelerating Growth: SH0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SH0 had negative earnings growth (-29.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).

Return on Equity

High ROE: SH0's Return on Equity (11.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shionogi & Co., Ltd. is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research